Several systemic treatments—including hormonal therapies and retinoids—have shown benefit in clinical studies. Tetracyclines are recommended for mild to moderate HS for a typical 12-week course or as long-term maintenance when appropriate.⁶ A combination of clindamycin and rifampin is considered an effective second-line approach for mild to moderate cases and may also serve as a first-line or adjunctive option in severe disease.⁶ For patients with moderate to severe HS, a regimen of moxifloxacin, metronidazole, and rifampin is suggested as a second- or third-line therapy.⁶ Dapsone may provide long-term maintenance benefits for individuals with Hurley stage I or II HS.⁶
Hormonal therapies—such as estrogen-containing oral contraceptives, spironolactone, cyproterone acetate, metformin, and finasteride—may be suitable for select female patients and can be used alone in mild to moderate disease or in combination with other treatments for more severe cases.⁶ Some reports suggest that progestin-only contraceptives may worsen HS and should be used cautiously.⁶ Evidence for isotretinoin is mixed, so it is best reserved as a second- or third-line therapy, particularly in patients who also have severe acne.⁶ Acitretin may be more effective than isotretinoin for HS, although robust comparative data are lacking; it is likewise considered a second- or third-line medication.⁶
Immunomodulators represent another category of potential treatments. Current evidence does not support methotrexate or azathioprine for HS.⁶ Limited data indicate that combining colchicine with minocycline may help in certain refractory mild to moderate cases, although colchicine alone is not advised.⁶ Cyclosporine may be considered for treatment-resistant moderate to severe disease when other systemic therapies are not effective or feasible.⁶ Short courses of systemic corticosteroids may help manage acute flares or serve as temporary bridging therapy.⁶ In severe cases, long-term systemic steroids—tapered to the lowest effective dose—may be added when standard therapies do not achieve adequate control.⁶
Growing interest has also focused on the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway—a rapid intracellular signaling system that regulates genes involved in inflammation and cancer.⁶ Because multiple cytokines implicated in HS rely on this pathway, JAK inhibition represents a promising therapeutic direction. ⁶
INCB054707, a JAK1 inhibitor, has undergone evaluation in 2 phase 2 trials (NCT04476043; NCT05620836) in patients with moderate to severe HS.⁶ The drug demonstrated good tolerability and clinical response, although significant improvement was seen only with the highest dose (90 mg), where 88% of patients achieved HS clinical response (HiSCR) vs 57% in the placebo arm.⁶
Upadacitinib, a second-generation selective JAK1 inhibitor, has shown promising results in a retrospective cohort study, with 75% of patients achieving HiSCR at 4 weeks and 100% at 12 weeks.⁶ HiSCR75 rates reached 30% at 4 weeks and 95% at 12 weeks.⁶ These findings led to the initiation of a phase 2 randomized controlled trial (NCT04430855), which is still ongoing.⁶ A separate phase 2 study (NCT05635838) is also underway to investigate topical ruxolitinib (a JAK1/JAK2 inhibitor) for early HS lesions.⁶
Biologic therapies have likewise demonstrated substantial benefits for individuals with moderate to severe HS. Table 2 outlines the available biologic options for managing HS.7,8
Table 2. Baseline Patient Characteristics, Efficacy, and Safety From Phase 3 Clinical Trials of Approved Therapies7,8
≥ 3 inflammatory nodules and/or abscesses at baseline
No concomitant oral antibiotics
Concomitant oral antibiotic (tetracycline) permitted (stable dose for ≥ 28 days prior to baseline)
≥ 5 inflammatory nodules and/or abscesses for ≥ 1 year
Daily use of topical antiseptic wash
Previous TNF-α experience and concomitant oral antibiotic use permitted
≥ 5 inflammatory nodules and/or abscesses at both screening and baseline visits
Documented inadequate response to systemic antibiotics
Previous TNF-α experience and concomitant oral antibiotic use permitted
Opioid analgesic use for HS-related pain
Draining fistula count > 6
Active ongoing skin condition that could interfere with HS assessment
Draining fistula count > 6
Ongoing active conditions requiring treatment with systemic biologics, live vaccines, or other investigational treatments
Draining fistula count > 6
Active ongoing skin condition that could interfere with HS assessment
Adalimumab 40 mg once weekly (n = 13)
Adalimumab 40 mg qw (n = 163)
Secukinumab 300 mg once every 2 weeks (n = 31)
Secukinumab 300 mg once every 4 weeks (n = 30)
Secukinumab 300 mg once every 2 weeks (n = 30)
Secukinumab 300 mg once every 4 weeks (n = 30)
Bimekizumab 36 mg once every 2 weeks (n = 289)
Bimekizumab 36 mg once every 4 weeks (n = 144)
Bimekizumab 36 mg once every 2 weeks (n = 291)
Bimekizumab 36 mg once every 4 weeks (n = 144)
Efficacy (achievement of primary end point for active treatment vs placebo)
(Once every 2 weeks, once every 4 weeks vs placebo)
(Once every 2 weeks, once every 4 weeks vs placebo
(Once every 2 weeks,a once every 4 weeksb vs placebo)
(Once every 2 weeks, once every 4 weeks vs placebo)
Statistical approach to missing data
Missing assessments handled with nonresponder imputation
Patients requiring rescue therapy with antibiotics considered nonresponders
Missing assessments handled with nonresponder imputation
Patients requiring rescue therapy with antibiotics considered nonresponders
Missing assessments handled with nonresponder imputation
Patients requiring new systemic antibiotic therapy (among those who were not receiving antibiotics at baseline) or any change in dose of systemic antibiotics (among those who were receiving systemic antibiotics at baseline) were considered non-responders
Headache (9%–10% in each group)
Oral candidiasis (1%–8%)d
HiSCR50, Hidradenitis Suppurativa Clinical Response 50; HS, hidradenitis suppurativa; TNF-α, tumor necrosis factor-α.
aP < .01 vs placebo
bP < .05 vs placebo
cDoes not include worsening HS
dBimekizumab groups only; no cases reported in placebo group
Conclusion
HS is a long-standing inflammatory condition that places a significant burden on those who live with it. Numerous studies highlight the many associated comorbidities, including cardiovascular disease, type 2 diabetes, mental health disorders, and disturbances in sleep and sexual function.³ Although newer therapeutic strategies—ranging from topical and surgical treatments to biologic agents and laser therapies—are emerging, many patients still face substantial obstacles in accessing these options. This underscores the need for improved recognition of HS in primary care settings and earlier, evidence-based treatment initiation to optimize patient outcomes.
Ferwa Mohammed, PA-C, MSPAS, is a board-certified physician assistant practicing in Wesley Chapel, Florida.
Disclosures: The author has nothing to disclose.
References
- Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058. doi:10.1016/j.jaad.2019.08.090
- Patel ZS, Hoffman LK, Buse DC, et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa. Curr Pain Headache Rep. 2017;21(12):49. doi:10.1007/s11916-017-0647-3
- Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50-61. doi:10.1111/jdv.16677
- Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157(8):924-931. doi:10.1001/jamadermatol.2021.1677
- Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019-2032. doi:10.1001/jama.2017.16691
- Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545-552. doi:10.2147/CCID.S402453
- Vellaichamy G, Amin AT, Dimitrion P, et al. Recent advances in hidradenitis suppurativa: role of race, genetics, and immunology. Front Genet. 2022;13:918858. doi:10.3389/fgene.2022.918858
- Garg A, Hsiao J, Porter ML, Shi V. Current treatments and future directions for hidradenitis suppurativa: a narrative review of completed and ongoing phase 3 clinical trials of biologic therapies. Dermatol Ther (Heidelb). 2025;15(9):2361-2377. doi:10.1007/s13555-025-01487-y